The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 ...

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients. The company announced on Friday that the FDA had approved the ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

This was accelerated by demand for its cancer blockbuster drugs Imfinzi, Tagrisso and Calquence. Analysts had expected core earnings per share at $2.04 on sales of $13.1 billion, according to a ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...